Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
DRJ Kuypers, Y Le Meur, M Cantarovich… - Clinical journal of the …, 2010 - journals.lww.com
With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …
for more accurate drug dosing has become evident. Personalized immunosuppressive …
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …
New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug …
H de Jonge, M Naesens… - Therapeutic drug …, 2009 - journals.lww.com
Although therapeutic drug monitoring (TDM) of immunosuppressive drugs has been an
integral part of routine clinical practice in solid organ transplantation for many years …
integral part of routine clinical practice in solid organ transplantation for many years …
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure
This article summarizes part of a consensus meeting about mycophenolate (MPA)
therapeutic drug monitoring held in Rome under the auspices of The Transplantation …
therapeutic drug monitoring held in Rome under the auspices of The Transplantation …
Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation
FH Calmet, AJ Yarur, G Pukazhendhi… - … publication of the …, 2015 - pmc.ncbi.nlm.nih.gov
Background Mycophenolate mofetil (MMF) is an immunosuppressive agent commonly used
after organ transplantation. Gastrointestinal side effects occur in approximately 45% of …
after organ transplantation. Gastrointestinal side effects occur in approximately 45% of …
Genetic polymorphisms affecting tacrolimus metabolism and the relationship to post-transplant outcomes in kidney transplant recipients
F Cheng, Q Li, J Wang, M Hu, F Zeng… - Pharmacogenomics …, 2021 - Taylor & Francis
Background Tacrolimus is a key drug in kidney transplantation with a narrow therapeutic
index. However, whether tacrolimus exposure variability affects clinical outcomes and …
index. However, whether tacrolimus exposure variability affects clinical outcomes and …
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
DA Hesselink, RHN van Schaik… - Pharmacogenetics …, 2008 - journals.lww.com
Objective Patients expressing the tacrolimus-metabolizing enzyme, cytochrome P450 (CYP)
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …
Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft …
DRJ Kuypers, H de Jonge, M Naesens, H de Loor… - Clinical …, 2008 - Elsevier
Background: Two recent randomized clinical trials—Fixed Dose Versus Concentration
Controlled and the Apomygre—evaluating the benefit of therapeutic drug monitoring of …
Controlled and the Apomygre—evaluating the benefit of therapeutic drug monitoring of …
Diarrhea after kidney transplantation: a new look at a frequent symptom
F Aulagnon, A Scemla, S DeWolf, C Legendre… - …, 2014 - journals.lww.com
Diarrhea is a frequent but overlooked complication of kidney transplantation. Diarrhea is
repeatedly neglected, often considered by patients and clinicians an unavoidable side effect …
repeatedly neglected, often considered by patients and clinicians an unavoidable side effect …
The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose …
JM Grinyó, H Ekberg, RD Mamelok… - Nephrology Dialysis …, 2009 - academic.oup.com
Background. Exposure to mycophenolic acid (MPA), the primary active metabolite of
mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies …
mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies …